Avalo Therapeutics Board Member Adds 20K Stock Options in 2025 Grant

Rhea-AI Filing Summary

Form 4 overview: Avalo Therapeutics, Inc. (AVTX) filed a Form 4 disclosing an equity-based compensation grant to board member Samantha Truex on 06/17/2025. The filing reports no sales or disposals of common stock; it solely records the award of new derivative securities.

Key terms of the option grant

• Security: Stock Option (Right to Buy) on AVTX common shares
• Underlying shares: 20,100
• Exercise price: $4.47 per share
• Vesting schedule: 100 % cliff vest on the first anniversary of the grant date, conditional on Ms. Truex’s continued board service
• Expiration: 06/17/2035 (10-year term)
• Ownership form after transaction: Direct

The transaction increases Ms. Truex’s derivative beneficial ownership to 20,100 options. No non-derivative (common stock) positions are listed in this filing, and there is no indication of Rule 10b5-1 trading plan use.

Investor takeaway: The filing reflects routine board compensation rather than market activity. While the additional options further align the director’s incentives with shareholders, the relatively small size (≈20 k shares) suggests limited immediate impact on AVTX’s share float or insider-sentiment signals.

Positive

• No insider selling reported; the filing only records an option grant, which may be viewed as strengthening director–shareholder alignment.

Negative

• None.

Insights

Financial Analyst

TL;DR Routine board option grant—20,100 shares at $4.47—neutral impact, no insider selling.

The Form 4 shows Avalo Therapeutics granted Director Samantha Truex 20,100 stock options at a $4.47 strike. The 10-year option, vesting fully after one year, is standard board compensation and signals no change in insider sentiment because there are no accompanying share purchases or disposals. Given Avalo’s historical trading volume and likely share count, the grant is immaterial to dilution. Investors may view continued equity-based compensation as governance-aligned, yet it does not meaningfully alter valuation or risk profile. Absent other insider activity, I classify the disclosure as neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Truex Samantha

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.47	06/17/2025		A		20,100		(1)	06/17/2035	Common Stock	20,100	$0	20,100	D

Explanation of Responses:

1. The stock option vests 100% on the first anniversary of the date of grant, subject to the Eligible Director's continued service on such vesting date.

	/s/ Donald R. Reynolds, by Power of Attorney	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Avalo Therapeutics (AVTX) disclose in the latest Form 4?

AVTX reported granting Director Samantha Truex 20,100 stock options on 06/17/2025.

What is the exercise price of the options granted to Samantha Truex?

The exercise price is $4.47 per share.

When do the options granted to the AVTX director vest and expire?

They vest 100 % on the first anniversary of the 06/17/2025 grant and expire on 06/17/2035.

Did the Form 4 report any sale or disposal of AVTX shares?

No. The filing shows no sales or disposals; it only records an option award.

How many derivative securities does Samantha Truex own after the reported transaction?

She beneficially owns 20,100 stock options following the grant.